Blog: Research

NICE pauses final decision on ocrelizumab for primary progressive MS

2 November 2018

Source MS Trust: NICE has announced that it is pausing the publication of final guidance for ocrelizumab for primary progressive multiple sclerosis.

Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis

19 October 2018

Source Neurology Advisor: Increased levels of physical activity may lead to decreased vascular risk profiles in patients with multiple sclerosis, according to a literature review published in Multiple Sclerosis and Related Disorders.

Researchers in this review searched for published articles in 5 major databases for studies involving physical activity, sedentary lifestyles, or exercise training and the impact these factors have on vascular comorbidities in patients with multiple...

Novartis files MS drug siponimod in EU and US

10 October 2018

Source PharmaTimes: "Siponimod is the first investigational medicine to show a significant delay in disability progression in typical SPMS patients," said Paul Hudson, chief executive of Novartis Pharmaceuticals. "We are closely working with the FDA and EMA to ensure siponimod is available for patients as soon as possible."

Encouraging news for people with primary or secondary progressive MS

3 October 2018

Source F1000 Prime: Fox et al. present the results of the eagerly awaited SPRINT-MS trial – a multi-centre phase II double blinded placebo controlled study of ibudilast in decreasing brain atrophy in progressive forms of multiple sclerosis (MS).

Link between smoking and MS clearer than ever

25 September 2018

Source MS Society: Our new evidence review shows the link between smoking and MS is clearer than ever.

Final results from the MS Risk Sharing Scheme (RSS) published

25 September 2018

Source MS Trust: The MS Trust has praised the pioneering work of the MS Risk Sharing Scheme (RSS) as the final results from the scheme are published in the BMJ today (September 24).

Study shows that drug slows brain shrinkage in multiple sclerosis

12 September 2018

Source UAB News: Results from a clinical trial of more than 250 participants with progressive multiple sclerosis revealed that ibudilast was better than a placebo in slowing down brain shrinkage.

The study also showed that the main side effects of ibudilast were gastrointestinal and headaches. The study was supported by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, and was published in the New England Journal of Medicine....

A further request from a first year PhD student at King's College London

12 September 2018

Your post helped us get so many helpful responses last time, and I was wondering if you would be able to help us post again for newly developed rating tasks- it is extremely similar to the last rating tasks, this time it is rating scenarios.

Pages

Category

Archive